Research Article 
Atherosclerosis in a managed care plan: hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring
James McKenney, Sanjay K. Gandhi, Kathleen M. Fox and Robert L. Ohsfeldt
Journal of Clinical Lipidology, 2009, 3(6), 385-392. DOI: 10.1016/j.jacl.2009.10.004
Abstract
Background
Clinical guidelines have recommended a LDL-C goal of <100 mg/dL for high-risk individuals and lipid-modifying therapy for patients not reaching this goal.
Objective
This investigation assessed low-density lipoprotein cholesterol (LDL-C) levels and treatment patterns among patients diagnosed with atherosclerosis with or without a previous cardiovascular disease (CVD) event.
Methods
We conducted a retrospective study by using claims data from a national health plan that included patients with ≥ 1 medical claim for atherosclerosis (ICD-9 of 440.xx, 414.x, 437.0, 437.1, or 437.3) between January 2004 and March 2006. Use of lipid-modifying medications at the time of diagnosis and thereafter, patient demographics, comorbid conditions, baseline, and postdiagnosis LDL-C were assessed.
Results
There were 311,567 patients who had an atherosclerosis ICD-9 code, 46% of whom had a previous CVD event. Among patients with an atherosclerosis diagnosis and CVD event, lipid-modifying therapy was received by 50% before diagnosis and 57% after diagnosis, compared with 37% before and 48% after diagnosis for patients with an atherosclerosis diagnosis and no previous CVD event. Of the patients with baseline LDL-C (15%, n=46,923), 44% had an LDL-C <100 mg/dL at diagnosis; of those with LDL-C ≥ 100 mg/dL, only 54% received lipid-modifying therapy and only 64% achieved an LDL-C <100 mg/dL in the 12 succeeding months. Among patients with baseline and postdiagnosis LDL-C values (n=24,724), 55% had a baseline LDL-C ≥ 100 mg/dL and 46% had a baseline non-HDL-C ≥ 130 mg/dL.
Conclusions
In conclusion, many patients in a managed care plan diagnosed with atherosclerosis with or without a previous CVD event present opportunities for better lipid management. Healthcare providers should evaluate more aggressive lipid management interventions for these patients for potential downstream cardiovascular benefits.
ASCI-ID: 2746-121
Similar Articles
High-density lipoprotein, sphingosine 1-phosphate, and atherosclerosis
Journal of Clinical Lipidology, 2008, 2(1), 4-11. DOI: 10.1016/j.jacl.2007.11.002
Coronary heart disease risk factors and atherosclerosis in young peopleJournal of Clinical Lipidology, 2008, 2(3), 118-126. DOI: 10.1016/j.jacl.2008.02.006
Getting the word out: Teaching middle-school children about cardiovascular diseaseJournal of Clinical Lipidology, 2008, 2(3), 179-188. DOI: 10.1016/j.jacl.2008.03.004
Flushing and the HDL-C response to extended-release niacinJournal of Clinical Lipidology, 2008, 2(4), 285-288. DOI: 10.1016/j.jacl.2008.05.002
Medical management of patients before the incidence of a cardiovascular eventJournal of Clinical Lipidology, 2009, 3(5), 315-321. DOI: 10.1016/j.jacl.2009.08.002
Prevention of atherosclerosis with low-density lipoprotein cholesterol lowering-lipoprotein changes and interactions: the SANDS studyJournal of Clinical Lipidology, 2009, 3(5), 322-331. DOI: 10.1016/j.jacl.2009.09.001
High plasma high-density lipoprotein levels, very low cardiovascular risk profile, and subclinical carotid atherosclerosis in postmenopausal womenJournal of Clinical Lipidology, 2009, 3(5), 345-350. DOI: 10.1016/j.jacl.2009.08.003
High-density lipoproteins: Marker of cardiovascular risk and therapeutic targetJournal of Clinical Lipidology, 2010, 4(5), 359-364. DOI: 10.1016/j.jacl.2010.08.002
Functions of cholesterol ester transfer protein and relationship to coronary artery disease riskJournal of Clinical Lipidology, 2010, 4(5), 389-393. DOI: 10.1016/j.jacl.2010.08.006
Update on CETP inhibitionJournal of Clinical Lipidology, 2010, 4(5), 394-398. DOI: 10.1016/j.jacl.2010.08.003
Emerging high-density lipoprotein infusion therapies: Fulfilling the promise of epidemiology?Journal of Clinical Lipidology, 2010, 4(5), 399-404. DOI: 10.1016/j.jacl.2010.08.018
Associations among smoking status, lifestyle and lipoprotein subclassesJournal of Clinical Lipidology, 2010, 4(6), 522-530. DOI: 10.1016/j.jacl.2010.09.003
Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart diseaseJournal of Clinical Lipidology, 2011, 5(3), 141-151. DOI: 10.1016/j.jacl.2011.02.003
Carotid intima-media thickness for the practicing lipidologistJournal of Clinical Lipidology, 2010, 4(1), 24-35. DOI: 10.1016/j.jacl.2009.11.004
Impact of lipid profile and high blood pressure on endothelial damageJournal of Clinical Lipidology, 2011, 5(6), 460-466. DOI: 10.1016/j.jacl.2011.06.005
Effect of Aggressive Cardiovascular Risk Factor Treatment on Progression of Carotid Intima-Media Thickness: Experience of an Atherosclerosis CenterJournal of Clinical Lipidology, 2012, 6(3), 262-263. DOI: 10.1016/j.jacl.2012.04.027
Serum apolipoprotein A-V in patients with coronary artery disease and its association with triglycerideJournal of Clinical Lipidology, 2012, 6(5), 462-468. DOI: 10.1016/j.jacl.2012.02.004
Relationships between alcohol intake and atherogenic indices in womenJournal of Clinical Lipidology, 2013, 7(5), 454-462. DOI: 10.1016/j.jacl.2013.03.009
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemiaJournal of Clinical Lipidology, 2013, 7(6), 561-565. DOI: 10.1016/j.jacl.2013.10.001
A kindred with fish eye disease, corneal opacities, marked high-density lipoprotein deficiency, and statin therapyJournal of Clinical Lipidology, 2014, 8(2), 223-230. DOI: 10.1016/j.jacl.2013.11.005
Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: A case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS)Journal of Clinical Lipidology, 2014, 8(5), 489-493. DOI: 10.1016/j.jacl.2014.07.004
Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practiceJournal of Clinical Lipidology, 2008, 2(1), 36-429. DOI: 10.1016/j.jacl.2007.12.006
Lipid therapy utilization rates in a managed-care mixed dyslipidemia populationJournal of Clinical Lipidology, 2008, 2(5), 365-374. DOI: 10.1016/j.jacl.2008.08.443
Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetesJournal of Clinical Lipidology, 2008, 2(1), 25-35. DOI: 10.1016/j.jacl.2008.01.001
Add-on therapy for hypercholesterolemia: a pilot comparison of two gastrointestinally-acting agents in statin-treated patientsJournal of Clinical Lipidology, 2009, 3(2), 119-124. DOI: 10.1016/j.jacl.2009.02.008
Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentrationJournal of Clinical Lipidology, 2009, 3(4), 275-280. DOI: 10.1016/j.jacl.2009.06.004
Clinical perspective: Have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidologyJournal of Clinical Lipidology, 2011, 5(3), 124-132. DOI: 10.1016/j.jacl.2011.02.006
Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patientsJournal of Clinical Lipidology, 2011, 5(3), 179-187. DOI: 10.1016/j.jacl.2011.02.009
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reductionJournal of Clinical Lipidology, 2012, 6(2), 180-191. DOI: 10.1016/j.jacl.2011.11.007
Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levelsJournal of Clinical Lipidology, 2012, 6(5), 434-442. DOI: 10.1016/j.jacl.2012.04.002
Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndromeJournal of Clinical Lipidology, 2013, 7(4), 292-303. DOI: 10.1016/j.jacl.2013.03.007
JCL Roundtable: Diagnosis of severe familial hypercholesterolemiaJournal of Clinical Lipidology, 2013, 7(6), 540-545. DOI: 10.1016/j.jacl.2013.08.003
Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care settingJournal of Clinical Lipidology, 2013, 7(5), 399-407. DOI: 10.1016/j.jacl.2013.06.002
Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A reviewJournal of Clinical Lipidology, 2012, 6(1), 5-18. DOI: 10.1016/j.jacl.2011.10.018
JCL Roundtable: Drug treatment of severe forms of familial hypercholesterolemiaJournal of Clinical Lipidology, 2014, 8(1), 10-17. DOI: 10.1016/j.jacl.2013.09.004
Lipid-altering effects of different formulations of hydroxypropylmethylcelluloseJournal of Clinical Lipidology, 2009, 3(3), 159-166. DOI: 10.1016/j.jacl.2009.04.053
Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: The Stop Atherosclerosis in Native Diabetics Study (SANDS)Journal of Clinical Lipidology, 2010, 4(3), 165-172. DOI: 10.1016/j.jacl.2010.01.008
Attainment of low-density lipoprotein cholesterol goals in coronary artery diseaseJournal of Clinical Lipidology, 2010, 4(3), 173-180. DOI: 10.1016/j.jacl.2010.03.002
Clinical and laboratory assessment of cardiovascular risk in children: Guidelines for screening, evaluation, and treatmentJournal of Clinical Lipidology, 2008, 2(4), 248-266. DOI: 10.1016/j.jacl.2008.06.003
Plasma lipids in Nigerians with systemic arterial hypertensionJournal of Clinical Lipidology, 2008, 2(4), 274-278. DOI: 10.1016/j.jacl.2008.03.002
Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular eventsJournal of Clinical Lipidology, 2008, 2(5), 343-353. DOI: 10.1016/j.jacl.2008.06.009
Increasing lipid adherence to goalJournal of Clinical Lipidology, 2008, 2(5), 354-359. DOI: 10.1016/j.jacl.2008.06.010
Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analysesJournal of Clinical Lipidology, 2008, 2(2), 91-105. DOI: 10.1016/j.jacl.2008.02.002
Plasma coenzyme Q10 predicts lipid-lowering response to high-dose atorvastatinJournal of Clinical Lipidology, 2008, 2(4), 289-297. DOI: 10.1016/j.jacl.2008.05.001
Lipoprotein changes in HIV-infected antiretroviral-naive individuals after starting antiretroviral therapy: ACTG Study A5152sJournal of Clinical Lipidology, 2008, 2(6), 464-471. DOI: 10.1016/j.jacl.2008.08.442
Lipoprotein particle profiles by nuclear magnetic resonance spectroscopy in medically underserved HIV-infected personsJournal of Clinical Lipidology, 2009, 3(6), 379-384. DOI: 10.1016/j.jacl.2009.10.005
Is directly measured low-density lipoprotein clinically equivalent to calculated low-density lipoprotein?Journal of Clinical Lipidology, 2010, 4(4), 259-264. DOI: 10.1016/j.jacl.2010.05.003
Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patientsJournal of Clinical Lipidology, 2010, 4(4), 272-278. DOI: 10.1016/j.jacl.2010.05.002
Achieving lipid targets in adults with type 2 diabetes: The Stop Atherosclerosis in Native Diabetics StudyJournal of Clinical Lipidology, 2010, 4(5), 435-443. DOI: 10.1016/j.jacl.2010.07.007
The effects of adherence and persistence on clinical outcomes in patients treated with statins: A systematic reviewJournal of Clinical Lipidology, 2010, 4(6), 462-471. DOI: 10.1016/j.jacl.2010.08.026
Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006Journal of Clinical Lipidology, 2010, 4(6), 483-490. DOI: 10.1016/j.jacl.2010.10.002
Differences in lipoprotein particle subclass distribution for Japanese Americans in Hawaii and Japanese in Japan: The INTERLIPID StudyJournal of Clinical Lipidology, 2011, 5(1), 30-36. DOI: 10.1016/j.jacl.2010.11.007
Comparative prognostic utility of conventional and novel lipid parameters for cardiovascular disease risk prediction: Do novel lipid parameters offer an advantage?Journal of Clinical Lipidology, 2011, 5(2), 82-90. DOI: 10.1016/j.jacl.2010.12.001
Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart diseaseJournal of Clinical Lipidology, 2011, 5(3), 141-151. DOI: 10.1016/j.jacl.2011.02.003
Carotid intima-media thickness for the practicing lipidologistJournal of Clinical Lipidology, 2010, 4(1), 24-35. DOI: 10.1016/j.jacl.2009.11.004
An evaluation of alanine transaminase and creatine kinase elevations with the use of ezetimibe in an ambulatory care settingJournal of Clinical Lipidology, 2010, 4(6), 501-507. DOI: 10.1016/j.jacl.2010.08.024
The association of apolipoprotein E polymorphism and lipid levels in children with a family history of premature coronary artery diseaseJournal of Clinical Lipidology, 2012, 6(1), 81-87. DOI: 10.1016/j.jacl.2011.06.017
Lipid levels in obese and nonobese subjects as predictors of fasting and postload glucose metabolismJournal of Clinical Lipidology, 2012, 6(2), 132-138. DOI: 10.1016/j.jacl.2011.09.005
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemiaJournal of Clinical Lipidology, 2012, 6(3), 235-243. DOI: 10.1016/j.jacl.2011.11.004
Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003-2006Journal of Clinical Lipidology, 2012, 6(4), 325-330. DOI: 10.1016/j.jacl.2012.05.002
A meta-analysis of randomized controlled trials that compare the lipid effects of beef versus poultry and/or fish consumptionJournal of Clinical Lipidology, 2012, 6(4), 352-361. DOI: 10.1016/j.jacl.2012.01.001
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical settingJournal of Clinical Lipidology, 2013, 7(2), 102-108. DOI: 10.1016/j.jacl.2012.06.006
Lipids and lipoprotein ratios: Contribution to carotid intima media thickness in adolescents and young adults with type 2 diabetes mellitusJournal of Clinical Lipidology, 2013, 7(5), 441-445. DOI: 10.1016/j.jacl.2013.05.002
Pregnancy during adolescence has lasting adverse effects on blood lipids: A 10-year longitudinal study of black and white femalesJournal of Clinical Lipidology, 2012, 6(2), 139-149. DOI: 10.1016/j.jacl.2011.12.004
Hospital use and medical care costs up to 5 years after triglyceride lowering among patients with severe hypertriglyceridemiaJournal of Clinical Lipidology, 2012, 6(5), 443-449. DOI: 10.1016/j.jacl.2012.03.002
Correlation between serum lipids and 1-hour postload plasma glucose levels in normoglycemic individualsJournal of Clinical Lipidology, 2014, 8(2), 217-222. DOI: 10.1016/j.jacl.2013.12.003
Comparison of cardiovascular disease risk associated with 3 lipid measures in Japanese adultsJournal of Clinical Lipidology, 2014, 8(5), 501-509. DOI: 10.1016/j.jacl.2014.06.005
The SLIM study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined HyperlipidemiaJournal of Clinical Lipidology, 2009, 3(3), 167-178. DOI: 10.1016/j.jacl.2009.04.052
Attainment of low-density lipoprotein cholesterol goals in coronary artery diseaseJournal of Clinical Lipidology, 2010, 4(3), 173-180. DOI: 10.1016/j.jacl.2010.03.002
Point: Statins, plant sterol absorption, and increased coronary riskJournal of Clinical Lipidology, 2008, 2(4), 304-305. DOI: 10.1016/j.jacl.2008.06.005
Misperception among physicians and patients regarding the risks and benefits of statin treatment: the potential role of direct-to-consumer advertisingJournal of Clinical Lipidology, 2008, 2(1), 51-57. DOI: 10.1016/j.jacl.2008.01.002
Pediatric dyslipidemias: Prescription medication efficacy and safetyJournal of Clinical Lipidology, 2008, 2(3), 189-201. DOI: 10.1016/j.jacl.2008.04.008
Optimal management of lipids in diabetes and metabolic syndromeJournal of Clinical Lipidology, 2008, 2(5), 335-342. DOI: 10.1016/j.jacl.2008.08.444
Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemiaJournal of Clinical Lipidology, 2009, 3(1), 33-38. DOI: 10.1016/j.jacl.2008.12.007
NLA Symposium screening and treatment of familial hypercholesterolemia: How can we do better? Opening and introductionsJournal of Clinical Lipidology, 2010, 4(5), 335-337. DOI: 10.1016/j.jacl.2010.08.016
Familial hypercholesterolemia: Current treatment options and patient selection for low-density lipoprotein apheresisJournal of Clinical Lipidology, 2010, 4(5), 346-349. DOI: 10.1016/j.jacl.2010.08.013
Insights from recent meta-analysis: Role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progressionJournal of Clinical Lipidology, 2010, 4(5), 365-370. DOI: 10.1016/j.jacl.2010.08.008
Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapyJournal of Clinical Lipidology, 2011, 5(2), 97-104. DOI: 10.1016/j.jacl.2011.01.006
Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatinJournal of Clinical Lipidology, 2011, 5(1), 50-56. DOI: 10.1016/j.jacl.2010.11.001
Carotid intima-media thickness for the practicing lipidologistJournal of Clinical Lipidology, 2010, 4(1), 24-35. DOI: 10.1016/j.jacl.2009.11.004
No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statinsJournal of Clinical Lipidology, 2010, 4(4), 288-292. DOI: 10.1016/j.jacl.2010.02.011
Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006Journal of Clinical Lipidology, 2010, 4(6), 483-490. DOI: 10.1016/j.jacl.2010.10.002
Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemiaJournal of Clinical Lipidology, 2011, 5(6), 483-492. DOI: 10.1016/j.jacl.2011.09.001
The differential effect of statins on oxidative stress and endothelial function: Atorvastatin versus pravastatinJournal of Clinical Lipidology, 2012, 6(1), 42-49. DOI: 10.1016/j.jacl.2011.08.006
Management of familial hypercholesterolemia during pregnancy: Case series and discussionJournal of Clinical Lipidology, 2012, 6(1), 88-91. DOI: 10.1016/j.jacl.2011.08.005
Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin usersJournal of Clinical Lipidology, 2012, 6(3), 208-215. DOI: 10.1016/j.jacl.2012.03.003
Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidenceJournal of Clinical Lipidology, 2012, 6(5), 413-426. DOI: 10.1016/j.jacl.2012.04.003
Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levelsJournal of Clinical Lipidology, 2012, 6(5), 434-442. DOI: 10.1016/j.jacl.2012.04.002
Review of red yeast rice content and current Food and Drug Administration oversightJournal of Clinical Lipidology, 2013, 7(2), 117-122. DOI: 10.1016/j.jacl.2012.09.003
Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care settingJournal of Clinical Lipidology, 2013, 7(5), 399-407. DOI: 10.1016/j.jacl.2013.06.002
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemiaJournal of Clinical Lipidology, 2013, 7(6), 561-565. DOI: 10.1016/j.jacl.2013.10.001
Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemiaJournal of Clinical Lipidology, 2013, 7(5), 408-413. DOI: 10.1016/j.jacl.2013.06.010
Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statinsJournal of Clinical Lipidology, 2012, 6(2), 168-173. DOI: 10.1016/j.jacl.2011.12.008
The high-dose rosuvastatin once weekly study (The HD-ROWS)Journal of Clinical Lipidology, 2012, 6(4), 362-367. DOI: 10.1016/j.jacl.2011.11.002
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full reportJournal of Clinical Lipidology, 2014, 8(1), 29-60. DOI: 10.1016/j.jacl.2013.12.005
Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: A subanalysis of the USAGE studyJournal of Clinical Lipidology, 2014, 8(1), 69-76. DOI: 10.1016/j.jacl.2013.10.006
Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular diseaseJournal of Clinical Lipidology, 2014, 8(1), 107-116. DOI: 10.1016/j.jacl.2013.09.009
Register-based predictors of adherence among new statin users in FinlandJournal of Clinical Lipidology, 2014, 8(1), 117-125. DOI: 10.1016/j.jacl.2013.09.008
Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert ForumJournal of Clinical Lipidology, 2014, 8(2), 173-180. DOI: 10.1016/j.jacl.2014.01.001